Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.328 SEK | +3.69% | -24.20% | -44.01% |
Mar. 13 | Oncopeptides Plans SEK300 Million Rights Issue to Support Multiple Myeloma Drug Commercialization | MT |
Feb. 27 | Transcript : Oncopeptides AB, Q4 2023 Earnings Call, Feb 27, 2024 |
Sales 2023 | 35.2M 3.36M | Sales 2024 * | 81.98M 7.82M | Capitalization | 395M 37.66M |
---|---|---|---|---|---|
Net income 2023 | -249M -23.75M | Net income 2024 * | -213M -20.31M | EV / Sales 2023 | 18.7 x |
Net cash position 2023 | 66.92M 6.38M | Net cash position 2024 * | 220M 20.98M | EV / Sales 2024 * | 2.13 x |
P/E ratio 2023 |
-2.78
x | P/E ratio 2024 * |
-3.73
x | Employees | 57 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 89.21% |
Latest transcript on Oncopeptides AB
1 day | +3.69% | ||
1 week | -24.20% | ||
Current month | -11.13% | ||
1 month | -41.88% | ||
3 months | -44.97% | ||
6 months | -45.94% | ||
Current year | -44.01% |
Managers | Title | Age | Since |
---|---|---|---|
Sofia Heigis
CEO | Chief Executive Officer | 44 | 20-07-31 |
Director of Finance/CFO | 50 | Nov. 12 | |
Klaas Bakker
CTO | Chief Tech/Sci/R&D Officer | 42 | 19-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Per Wold-Olsen
CHM | Chairman | 76 | 18-05-16 |
Director/Board Member | 63 | 11-12-31 | |
Director/Board Member | 61 | 17-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-19 | 4.288 | +2.73% | 75 120 |
24-03-18 | 4.174 | +2.50% | 261,246 |
24-03-15 | 4.072 | -10.90% | 869,982 |
24-03-14 | 4.57 | -8.96% | 420,124 |
24-03-13 | 5.02 | -11.28% | 1,463,061 |
Delayed Quote Nasdaq Stockholm, March 19, 2024 at 07:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.01% | 37.81M | |
+1.10% | 106B | |
+9.29% | 103B | |
-2.85% | 21.44B | |
-11.89% | 22.11B | |
-26.59% | 20.99B | |
-6.13% | 19.44B | |
-6.58% | 17.6B | |
+5.83% | 13.88B | |
+7.46% | 11.75B |